Newly listed or thinly covered: fundamentals appear here once there is enough reported history. Prices and market cap are up to date.
Share price
₹430.45 latest close · +25.5% over the last 90 sessions
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-26.9% (2026-10 peak to 2026-11 low, not yet recovered)
-19.7% (2026-08 peak to 2026-08 low, recovered 2026-10)
Most recent volume spikes
2026-10-06: 6x the 50-day median, price +2.2% that day
2026-09-29: 31.7x the 50-day median, price +15.0% that day
2026-09-28: 20.8x the 50-day median, price +2.3% that day
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE74th
- Op. margin42nd
- Debt/equity ↓45th
- Cash cycle ↓32nd
- P/E ↓76th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
At normalised P/E (five-year average earnings) of 73.5x, a holder earning 12%/yr needs earnings to grow about 30.9%/yr for 10 years, then trade at 15x.
Over time
Implied growth by month (solid) and delivered growth (dashed).
Change the assumptions
| Exit P/E / return | 11% | 12% | 13% |
|---|---|---|---|
| 12x | 32.6% | 33.8% | 34.9% |
| 15x | 29.7% | 30.9% | 32.0% |
| 20x | 26.1% | 27.2% | 28.4% |
Drag a slider to test other assumptions
Implied: 30.9%/yr“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹430.45
- P/E
- 21.2x
- ROCE
- 21.0%
- Market Cap
- ₹1266 cr
- Revenue (TTM)
- ₹511 cr
- P/S
- 2.5x
- P/B
- 3.1x
- ROE
- 14.7%
- Operating Margin
- 14.8%
- Debt / Equity
- 0.3x
- Promoter Holding
- 64.1%
Balance sheet & cash
Are profits backed by cash?
Other income reliance30%Near threshold
Other income as a share of pre-tax profit (trailing twelve months): 30.1%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate31%Within range
Median quarterly effective tax rate over about 2.5 years: 31.2%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.
Cash conversion1.96xWithin range
Operating cash flow divided by net profit over the last three fiscal years: 1.96x (cash from operations ₹239 cr, net profit ₹122 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.
Free cash flow5 of 5 yrsWithin range
Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress6% of fixed assetsWithin range
Capital work-in-progress is 6% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
What changed?
5 events since Jun '26
- NovPriceFell 27% from the Oct 2026 peak to the Nov 2026 low.
- OctPriceVolume reached 6.0x its 50-day median on 2026-10-06; price +2.2% that day.
- JulPriceVolume reached 156.9x its 50-day median on 2026-07-06; price +15.2% that day.
- JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
- JunPriceVolume reached 17.5x its 50-day median on 2026-06-08; price +2.6% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history8 months · 2026-04 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | 21.2x | ₹511 cr | 14.7% | 21.0% | 0.3x |
| 2026-10 | 20.6x | ₹511 cr | 14.3% | 21.0% | 0.3x |
| 2026-09 | 27.1x | ₹511 cr | 14.3% | 21.0% | 0.3x |
| 2026-08 | 20.5x | ₹525 cr | 17.3% | 21.0% | 0.3x |
| 2026-07 | 20.6x | ₹525 cr | 17.3% | 21.0% | 0.3x |
| 2026-06 | 14.6x | ₹525 cr | 17.3% | 21.0% | 0.3x |
| 2026-05 | 10.0x | ₹544 cr | 23.4% | 23.0% | 0.3x |
| 2026-04 | 10.5x | ₹544 cr | 23.4% | 23.0% | 0.3x |